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                                          Introduction
Minimal  hepatic  encephalopathy  (MHE)  is  the  earliest  stage  of hepatic 
encephalopathy  and  is  associated  with  changes  in  cognitive functions,  in 
electrophysiological  parameters  and  in  cerebral neurochemical/  neurotransmitter 
homeostasis.  MHE  can  be  observed in  patients  with  cirrhosis  who  have  no  clinical 
evidence of hepatic encephalopathy.
  Prevalence is estimated to be about 30% - 60% in cirrhotics without overt clinical 
signs of hepatic encephalopathy  1-7 . Probability of clinical hepatic encephalopathy after 
follow up of 3years was estimated to be 50% in patients with MHE compared to 8% in 
cirrhotics without MHE, whether this course of events is affected by early treatment needs 
to be studied.
MHE often manifested with sleep disturbances or subtle behavioral changes that 
are more apparent to the patient’s family than to the clinician. The behavioral changes are 
due  predominantly  to  subtle  impairment  of  cognitive  function  resulting  from  bilateral 
dysfunction of forebrain and parieto-occipital regions, because verbal abilities are usually 
preserved in this stage of hepatic encephalopathy. Cerebral dysfunction is not detectable 
by the routine clinical examination but only by neuropsychological or neurophysiological 
measures.
Patients  with  MHE  perform  worse  than  healthy  controls  especially  in  tests  of 
psychomotor speed, visual perception and attention. Some of these patients also show a 
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pathologic  slowing  of  the  electroencephalogram  (EEG)  and  prolonged  latencies  of 
exogenous (visual evoked potentials (VEP), somatosensory evoked 
potentials  (SSEP)  and brainstem  auditory  evoked  potentials  (BAEP)  and 
endogenous evoked potentials (P300).
Table 1.  Prevalence of MHE
Author (year) N Modality of diagnosis Prevalence    ( %)
Yen et al (1990) 97 NCT
BAEP
60
Groenweg et al (2000) 179 Psychometry
EEG
27
Das et al (2001) 165 Psychometry 63
Saxena et al (2001) 101 P300  auditory  evoked 
potential
21
Liu et al (2004) 97 NCT
BAEP
60
Sharma et al (2007) 156 P300  auditory  evoked 
potential
Psychometry
53
Prasad et al (2007) 90 Psychometry 68
 Although  undetectable  on  clinical  grounds  MHE  is  undoubtedly  of  clinical 
significance for the patients. It has been shown to interfere with the patient’s ability to drive 
a  car,  their  earning  capacity  and  their  quality  of  life.  Therefore  experts  in  the  field 
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discourage  the  use  of  the  terms  subclinical  encephalopathy  or  latent  hepatic 
encephalopathy. 
A consensus has emerged that patients with MHE should be treated. Only limited 
numbers of studies are available to analyze the importance of encephalopathy. Hence 
psychometric and neurophysiological tests to diagnose minimal hepatic encephalopathy. 
We  have  undertaken  this  study  to  find  out  the  prevalence  of  minimal  hepatic 
encephalopathy in patients with cirrhosis of different etiology.
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 AIM OF THE STUDY
              To find out the prevalence of Minimal Hepatic Encephalopathy in    cirrhotic 
patients with the help of Number connection test (NCT),   Electroencephalogram (EEG) 
And Brainstem auditory evoked potential (BAEP).
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REVIEW OF LITERATURE
          MHE has generated a lot of interest in recent years. There is increasing evidence to 
show that MHE is an important disorder that could seriously impair daily living and health 
related quality of life (HRQOL) in patients with cirrhosis.4, 5 Treatment with lactulose is of 
benefit as it improves both cognitive functions and HRQOL.8 Diagnosis of MHE requires a 
high index of suspicion.
           MHE is defined as the condition in which patients with liver cirrhosis show several 
quantifiable neuropsychological defects together with a normal neurological examination. 
The pathogenesis of MHE is not yet clear. 
         Treatment with lactulose is of benefit as it improves both cognitive functions and 
HRQOL. Treatment with synbiotics or fermentable fiber is an alternative to lactulose for 
management of MHE in patients with cirrhosis. Cirrhotic patients may be routinely 
screened for the presence and treatment of MHE.
         Subcortical alterations in the basal ganglia has been suggested as a possible 
anatomical site responsible for the subclinical changes of this entity. The selective 
reduction in glucose consumption in the area of the cyngulate gyrus, a nucleus involved in 
the attention process, coupled with focal alterations of cerebral perfusion support this 
hypothesis. On the other hand, the relation of subclinical changes to protein metabolism 
and plasma amino acid imbalance, the reduction in cerebral blood flow and the improved 
response of neuropsychological tests after therapeutic 
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manipulations which are applied in clinically overt HE, suggest the impact of the liver 
disease on brain function. 
         The incidence of MHE is estimated to vary from 30% to 84% in apparently healthy, 
non-encephalopathic cirrhotic patients, depending on the diagnostic criteria used.12-16 This 
large variation reflects the variability and the large number of tests used and, on the other 
hand, is related to the composition of the tested population in each study, especially to the 
severity and the etiology of their cirrhosis. Although the diagnosis of symptomatic HE is a 
diagnosis of exclusion, based mainly on a careful global and neuropsychiatric 
examination, MHE is not a clinically evident entity and thus, for their detection, requires 
specific neuropsychological and neurophysiological examination.
Historical aspects
         In 1957 Passons-Smith et al. identified the presence of definite
 Electroencephalographic (EEG) abnormalities in 43% of cirrhotic patients without overt 
Hepatic Encephalopathy. The authors did not realize the importance of their findings, 
which in effect defined the existence of a latent or preclinical stage of hepatic 
encephalopathy (HE).
      
           In 1970, Zeagen et al. observed that 62% of a cohort of patients who had 
undergone Porto-systemic shunt surgery showed impaired performance of the Trail-
Making Tests A and B even though their mental function was apparently normal. In 
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1978, Rikkers et al evaluated a group of cirrhotic patients who had undergone Porto-
systemic shunt surgery but whose mental state was deemed to be unimpaired; they 
observed EEG abnormalities in 33% and impaired psychometric performance in 60%. The 
authors coined the term subclinical Hepatic Encephalopathy.
Nomenclature and Grading of Hepatic encephalopathy
         Working Party at the 11th World Congress of Gastroenterology, Vienna under the 
Organisation Mondiale de Gastroentrologie proposed multiaxial definition of HE that 
defines both the type of hepatic abnormality and the duration/characteristics of 
neurological manifestations in chronic liver disease  HE has been considered a continuous 
dimension that could be measured
with one index to summarize several neurological domains, such as, cognition, emotion, 
behavior, or biologic rhythms. Minimal hepatic encephalopathy (MHE) would represent a 
portion of this dimension, would be the mildest form of HE, and would be diagnosed on 
the basis
of a cut-off score.
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   Table : 2  West Haven Staging of Hepatic Encephalopathy
Stage Criteria
0 No abnormality
1 Trivial lack of awareness; euphoria or anxiety; shortened attention span; impaired performance of 
addition
2 Lethargy or apathy; disorientation for time and place; subtle personality change; inappropriate 
behavior; impaired performance of subtraction
3 Somnolence to semi-stupor but responsive to stimuli; confusion; gross disorientation
4 Coma, mental state not testable
          Recently, use of the term subclinical HE has been criticized mainly because such a 
term might trivialize the condition because its presence has a detrimental effect on health 
related quality of life, may predict overt HE and may carry poor prognosis. Present 
consensus favors the term that was coined by Schomerus and Hamster. This term also 
signify that MHE represents the mildest form of HE and represent one end of the 
continuous dimension.
c
              Figure 1: Hepatic encephalopathy: A continuous dimension
          MHE is not a clinically evident entity and thus, for their detection, requires specific 
neuropsychological and neurophysiological examination.
Precipitating factors for Hepatic Encephalopathy
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          Evaluation should include work up to look for the precipitating factors and strict 
attention must be paid in treating following precipitating factors:
1. Infection: spontaneous bacterial peritonitis, urinary or respiratory tract infections; 
appropriate cultures are required.
2. Nitrogen overload: gastrointestinal bleed, uremia, constipation and or excessive 
consumption of proteins, etc; placement of nasogastric tube and stool analysis is required 
to exclude gastrointestinal bleed.
t
3. Metabolic: hypokalemia, alkalosis, hyponatremia, renal failure, dehydration: prompt 
identification followed by correction of these metabolic factors are mandatory.
4. Additional hepatic injury: portal vein thrombosis or superimposed hepatitis (viral, 
alcoholic or drug induced).
5. Drugs: opiates, benzodiazepines, sedatives, diuretics: urinary screening for narcotics or 
benzodiazepines may be required at times.
Pathogenesis of Hepatic Encephalopathy
         HE is a form of gliopathy caused due to swelling of Alzheimer type II astrocytes, the 
only cerebral cell capable of metabolizing ammonia. Ammonia and other intestinal 
neurotoxins, 39 manganese and the benzodiazepine-GABA system are the main 
substances implicated in the development of HE. Neurotransmission changes induced by 
these compounds play a major role
in the development of the neurologic disturbances presented in these patients. 
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          Ammonia remains the first key gut-derived neurotoxin implicated in the 
pathogenesis of HE; the highest concentrations are found in the portal vein. Ammonia, 
derived from colonic bacteria as well as from the deamination of glutamine in the small 
bowel, is absorbed by passive diffusion and undergoes a high first-pass extraction by the 
liver. In liver failure, hepatic urea synthesis declines and this, along with portal-systemic 
shunting, leads to increased arterial blood ammonia concentrations. Ammonia is primarily 
responsible for encephalopathy that has been substantiated by recent studies. 41,46 A study 
has shown that arterical NH3 levels > 
200 μg/dL in patients with stage III-IV encephalopathy was an accurate predictor of 
herniation in patients with acute liver failure.
          43 The blood-brain barrier permeability to ammonia is increased in patients with HE. 
Ammonia is detoxified in astrocytes by glutamine synthetase leading to formation of 
glutamine, the accumulation of which is the major cause of astrocyte swelling.
           44 Ammonia also effects the neurons by inducing neurosteroid production leading to a 
positive modulatory effect on the γ-aminobutyric and A (GABA-A) receptors leading to 
upregulation of peripheral benzodiazipine receptors thus causing a functional imbalance 
between the excitatory and inhibitory receptor systems. The upregulation of GABA-A 
receptors in HE is a form of denervation supersensitivity and is associated with decreased 
GABA at neuronal level rather than an increased GABA levels in blood and brain.
             Indeed, animal studies have shown that mild encephalopathy is characterized by 
a 45%-50% increase in the number of GABA receptors without change in the affinity 
constants. 45,46 These findings have recently been confirmed in humans where increased 
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central type benzodiazepine receptors and decreased cortical GABA levels were 
demonstrated in patients with recurrent HE. 47 Thus, these changes explain the 
supersensitivity to benzodiazepines in patients with acute and chronic liver disease. 
Hence ammonia induces HE by multiple mechanisms and is the main pathogenetic factor. 
 
          Natural benzodiazepines (NBZDs) such as diazepam and nordiazepam are 
naturally present in several plants, vegetables, and animal species and in humans. 48 
Microorganisms in gut flora like Acinatobacter lwoffi can also produce NBZDs. NBZDs are 
found in trace amount in normal subjects but may increase several fold in patients with 
cirrhosis. 48 A significant but 7 weak correlation between NBZDs and the degree of HE has 
been demonstrated by Basile and coworkers. 49 A recent study showed a 40% reduction in 
NBZDs levels after reduction in bacterial flora with riflaximin. 50 Thus NBZD might be 
contributing to the pathogenesis of HE.
 Neurophysiologic assessment of MHE 
          MHE is characterized by psychomotor slowing, disturbances of motor speed and 
accuracy  and  deficits  in  attention,  visual  perception  and  visual  orientation  and 
visuoconstructive abilities. Various studies have been performed to evaluate psychometric 
tests  together  with  or  without  neurophysiologic  measures  such  as  EEG  and  evoked 
potentials for their sensitivity and reliability in the diagnosis of MHE. Diagnostic approach 
to the assessment of MHE is not uniform and no gold standard exists.
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         Most of the studies recommend uniformly the administration of the same few tests 
such as, the NCT A & B, the digit symbol test or the block design test, a line training test 
and a serial dotting test. 
       NCT-B provided a higher sensitivity and specificity as the various neurophysiologic 
measures used. (EEG, VEP, P300)
       Since the beginning of the 1970s, more than sixty different diagnostic tests and eight 
test batteries have been proposed and used for the diagnosis of MHE, which can be 
classified in four major groups.
1. PSYCHOMETRIC OR NEUROPSYCHOLOGICAL TESTS
 
         Zeegen et al in the early 1970s, first demonstrated an abnormal score in 
approximately one third of 39 apparently healthy cirrhotic patients previously operated for 
portal decompression using the Reitan trail making tests.
        Thereafter, neuropsychologists have designed and used more than 25 psychometric 
tests for the detection of MHE with most common neuropsychological finding an 
impairment of motor speed and accuracy, accompanied with deficits in visual perception, 
visuospatial orientation, visual construction, concentration, attention and memory while the 
verbal ability is preserved. From all these psychometric examinations and according to the 
grade of their diagnostic accuracy, four can be considered as the most sensitive:
 I) the Number Connection Test
18
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    (NCT), available in two versions, part A and part B
ii) The Digit. Symbol Test (DST) 
iii) the Block Design Test
    (BlDes) and
 iv) the Reaction Time to Light or Sound
 
     Test (RT).
          Although psychometric tests are characterized by high sensitivity and simplicity in 
performance, their interpretation is not as easy as suggested because a number of factors 
can influence the overall score. A proposed correction using the adequate age normalized 
values is not the solution to the problem, because the final result is also influenced by the 
grade of cirrhosis, the educational level and the cultural background of the examined 
population, as well as subject to the effect of repeated learning.
           A history of alcohol abuse also induces a minor influence in MHE diagnosis, as 
reported by several investigators. Thus to abolish this effect, the use of different test 
variants of equal difficulty has been suggested. Taking into account that a different domain 
of cognitive functioning is measured by each psychometric test (NCT measures cognitive 
motor abilities, SDT motor speed and accuracy etc.) several authors have been proposed 
their use in combination (test batteries). The proposed comparison, between different 
neuropsychological domains can be also a useful diagnostic approach for this form of HE. 
But, despite the efforts and the progress, there is not yet a gold standard for the 
neuropsychological assessment of MHE. Although psychometric tests are characterized 
by high sensitivity, their specificity and their positive predictive value are low.
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        The newly developed computerized psychometric tests, Posner test, Sternberg 
Paradigm appear to be very promising tools, but experience is still limited. The statement 
of the Consensus conference of the 11th World Congress of 
Gastroenterology proposed that at least two of the following psychometric examinations 
should be used: 
NCT-A, NCT-B, BlDes, DST.
 
       A standardized test batteries that include the NCT-A and -B, the line-tracing test, the 
serial-dotting test and the DST (PSE-Syndrome-Test) is recommended.
20
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 Table 3 : Commonly used psychometric tests 11
Pschometric tests Measure
WAIS – Performance
1. Digit symbol
2. Block design
3. Picture completion
4. Picture arrangement
5. Object assembly
Nonverbal skills (performance intelligent quotient)
Motor speed and accuracy, short time visual memory
Visual spatial motor functioning
Basic perceptual and conceptual skills as
assessed through visual recognition and
identification
Trail making tests
1. Number connection test A
2. Number connection test B
3. Figure connection test A
4. Figure connection test B
Visuo-spatial orientation, motor speed, concentration
and attention
Canceling A’s test Preattentive visual processing
Digit span Attention
Line tracing test Visuo-motor co-ordination and psychomotor
slowing
Serial dotting test Motor speed and co-ordination
Simple reaction time to light Motor speed and co-ordination
Simple reaction time to sound Psychomotor speed in response to sound
Choice reaction time to light
Choice reaction time to sound
Psychomotor speed in response to a light or a sound
stimulus when either stimulus may occur, also
evaluates decision making time
e
2. ELECTROPHYSIOLOGICAL OR NEUROPHYSIOLOGICAL  TESTS
         Due to the disadvantages and the difficulties in interpretation of neuropsychological 
tests, the use of electrophysiological methods has been proposed as a more objective and 
specific method for the assessment of MHE. Although EEG is the most widely used 
neurophysiological diagnostic tool for the detection of clinically apparent HE, its diagnostic 
role in MHE is minor.
         With a percentage of abnormal examinations ranging between 8%-35% among 
cirrhotics without overt HE, it is considered less sensitive than psychometric tests, and its 
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changes are not specific, as in other metabolic encephalopathies. Additionally, 
psychotropic agents can induce similar alterations. For diagnosis of MHE, an elevated 
percentage of this activity is necessary. Quantitative and automated .spectral. EEG 
analysis is preferable to visual EEG analysis for the assessment of MHE, because it 
integrates the tracing and delineates the dominant signals.
Electroencephalogram ( EEG)
          EEG can be assessed by means of simple visual reading and by quantitative 
methods such as spectral analysis. EEG is best assessed using spectral rather than visual 
analysis because its repeatability is greater. An objective classification of EEG alterations 
in HE, which was based on
EEG parameters obtained by automatic quantitative spectral analysis, was proposed more 
recently by Van der Rijt et al 9. Such a technique increases the reliability of 
EEG assessment. In the absence of other causes, the alterations observed in the EEG in 
cirrhotic patients are assumed to reflect the presence of MHE, since they roughly correlate 
with plasma ammonia concentrations and other indices of hepatic dysfunction and predict 
the development of overt HE and liver related death, at least in patients with advanced 
liver disease.
         Apart from EEG, several investigators have used evoked potentials (EP) such as the 
P300 (P300 event related potentials), the SSEP (somatosensory-evoked potentials), the 
BAEP (brain stem auditory-evoked potentials) and the VEP (visual-evoked potentials) with 
a reported rate of abnormal findings in cirrhotics without overt HE ranging between 
14%-78%, 5%-34%, 0%-41% and 0%-63% respectively. With the exception of P300, their 
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sensitivity is unsatisfactory compared to that of psychometric tests and the specificity 
cannot be fully determined.
 
          Several parameters can be determined for the interpretation of their results that are 
expressed as time (in milliseconds) to positive or negative deflections, including peaks 
and latencies. In clinical practice, EP is not widely used because of the need for 
sophisticated equipment and neurophysiological knowledge.
              
              The P300 examination is an endogenous EP that is regarded as representing 
stimulus evaluation processes. In contrast to the conventional EPs, the response on P300 
does not depend on the physical properties of the stimulus, but rather on the meaning of 
the stimulus to the patient. In this test, the response to two different stimuli, visual and 
acoustic, is measured and the patient is asked to identify 
a predefined stimulus. A minimal hepatic encephalopathy prolongation of the P300 latency 
to acoustic stimuli is observed in patients with MHE.
           The Consensus conference of the 11th World Congress
Of Gastroenterology proposed: .When it is possible, quantitative neurophysiologic tools 
(like EEG with mean dominant frequency, P300 auditory evoked potentials) should be 
used. 
Event Related (Cognitive) Evoked Potentials
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         There are two kinds of evoked potentials, i.e., exogenous evoked potentials and 
endogenous event related potentials.
         Event related endogenous potentials occur secondary to the stimulus processing 
response. They occur independent of the type of stimulus, and are a measure of the 
cognitive function responsible for processing the response to a stimulus. Therefore these 
tests are sensitive in detecting subtle cognitive deficits, which are an integral part of the 
early stages of HE. Tests are carried out by giving either auditory or visual stimuli. 
         Two types of stimuli are used, the “common or the frequent stimuli” interspersed 
randomly which the “target or rare stimuli” in ratio of about 80:20 respectively. The patient 
is asked to concentrate on the target stimuli only and 
register them by counting or indicating in some way. Potentials occurring in response to 
this process are recorded. The event related P300 wave is the most consistent wave and 
can be considered the electrophysiological counterpart of the psychometric tests as both 
involve active use of the cognitive faculties.
        Saxena et al 6 showed P300 was altered in 20-80% of cirrhotic patients with no 
clinical evidence of HE or with grade I changes. They also demonstrated, in a follow up 
study that changes in P300 latency predicted the occurrence of overt HE. 
Critical Flicker Frequency
         Other methods applied for detection of MHE include measuring of the CFF threshold 
at which light pulses are perceived as fused. Kircheis et al 12 evaluated CFF in 92 patients 
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with cirrhosis. The investigation is based on the suggested pathogenesis of HE, that low-
grade astrocyte swelling is an early event and triggers HE by altering the glioneural 
communication. The authors
based their study on the hypothesis that retinal gliopathy could serve as a marker of 
cerebral gliopathy in HE. They also performed psychometric tests in these patients.
 
         The authors defined a cut-off between normal and pathologic CFF of 39 Hz. Using 
this frequency as cut-off, CFF analysis detected MHE in about 30% of cirrhotic patients 
compared with about 50% with psychometric tests. Authors recommended CFF as a 
simple and reliable test for the diagnosis of MHE after considering long time spent with 
psychometric tests. However, approximately 40% of the patients who were classified as 
MHE by the psychometric tests had normal CFF. Therefore, CFF 
alone may not be adequate for the detection of MHE. Further studies are required in this 
field to confirm the efficacy of this test and its value in relation to psychometry and other 
neurophysiological tests.
   Table 4 : Neurophysiological methods 11
1. Electroencephalogram (EEG)
        a. Standard
        b. Mean dominant frequency
2. Evoked potentials
        a. Exogenous
             i. Brainstem auditory evoked potentials (BAEP)
25
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            ii. Visual evoked potentials (VEP)
           iii. Somatosensory evoked potentials (SSEP)
        b. Event related potentials (P300)
             i. Visual paradigm
            ii. Auditory paradigm
3. Critical flicker frequency (CFF)
3. NEUROIMAGING TESTS
         Brain imaging provides no useful information for the Assessment of MHE.
         Computer tomography must be used only for differential diagnosis. Although cranial 
magnetic resonance imaging shows characteristic abnormalities in cirrhotic 
patients (symmetric pallidal hyperintensities in T1-weighted images), these changes do 
not correlate with the grade of encephalopathy.
        Proton magnetic resonance spectroscopy and positron emission tomography (PET) 
are two relatively new imaging methods and the experience in diagnosis of MHE with 
these is very limited.
 4. TEST OF CEREBRAL METABOLISM
         There is a very little data about tests of cerebral
Metabolism in the diagnosis of MHE. Clinical significance of MHE.
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 Impact on daily life: 
        The significance of MHE diagnosis is still a subject of debate. Several investigators 
have reported a negative influence on daily functioning. 
       Other studies suggest a possible relation between MHE and the subsequent 
development of episodes of overt HE. The reduction in the ability of these patients to carry 
out activities (driving a car, performing at work) probably reflects the neuropsychological 
deficits founded in MHE. It has been reported that a percentage of between 44% and 70% 
of cirrhotics with the diagnosis of MHE show an impairment in their ability to drive an 
automobile. On the other hand, other investigations did not revealed differences in quality 
of automobile driving between cirrhotics with MHE and healthy subjects.
 Quality of life:
 
        Patients with MHE experience a poor quality of life with serious difficulties in sleep, 
hobbies, recreation and deterioration of body care. The performance of SIP (Sickness 
Impact Profile) questionnaires showed Highest scores on the areas of social interaction, 
alertness, Emotional behavior, mobility, sleep/rest, home management  and recreation 
and pastimes. Sleep abnormalities are frequent in all cirrhotics and may be related to 
alterations of circadian function, or could reflect anxiety and depression as a result of 
living with chronic disease.
l
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 The prognostic value of MHE:
 
          The clinical repercussions Of detecting MHE are still unknown. A possible 
prognostic value of psychometric alterations in the subsequent development of overt HE 
and survival is suggested by several authors, but very few studies can confirm these 
statements. Most of these have been limited to patients with advanced liver disease 
(portal systemic shunts, decompensated cirrhosis) and the follow up time was very short: 
less than 12 months. Only two long term follow up studies have confirmed that MHE is an 
independent risk factor for the development of HE.  
        The predictive value of MHE on survival is also a subject of debate and the 
relationship between severity of liver disease and psychometric alterations is not yet 
clarified.
Diagnosis of MHE
        Various tools have been evaluated for the correct diagnosis of MHE and include the 
psychological tests, neurophysiological tests, regional cerebral blood flow changes and 
magnetic resonance spectroscopy. However, in the absence of a “gold standard” 
psychometric and Neurophysiological methods have been the most trusted and widely 
used tests. Combination of at least two psychometric ( trail making tests, block design or 
digit symbol test) and one neurophysiological test (P300 BAEP or electroencephalography 
with mean dominant frequency) appears to be optimal in detecting MHE.10, 11
1
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Diagnostic tools for MHE
          There are numerous modalities, which are used to diagnose MHE .66 However 
traditionally the diagnosis has been limited to the presence of neurological impairment 
demonstrated by neuropsychological assessment or neurophysiological tests .10,11,66
Table 5: Diagnostic methods for MHE66
Methods Advantages Disadvantages
Neuropsychological assessment Better recognition of
clinical significant
Subjective
Time consuming
Psychometric hepatic encephalopathy score 
(PHES)
Easy to use Few validating studies
? Learning effect
Neurophysiological tests(EEG, spectral EEG, 
evoked potential)
Objective tests
 Useful for repeated
testing 
Equipments required
Lack of information on
behavioral consequences 
computerized tests (Critical flicker frequency, 
reaction time)
Easy to apply Insufficient studies
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Diagnostic criteria for MHE
1. Confirmation of a disease that can cause MHE
    Cirrhosis
    Other: congenital portosystemic shunts, portal thrombosis.
2. Normal mental status on clinical examination
Absence of signs of overt encephalopathy; dysarthria, ataxia, flapping tremor, 
disorientation, obvious slow mental processing
3. Documentation of neurological impairment by
    Formal neuropsychological assessment
    Short neuropsychological battery
    Computerized tests
    Neurophysiological tests
4. Exclusion of other disturbances that may cause the     neurological     impairment
   Research studies: exclusion of participants with confounding  factors
   (active alcoholism, visual impairment, co morbidities, etc.)
  Clinical practice: judgment of the effect of confounding factors.
30
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Treatment of minimal hepatic encephalopathy
        The pathogenesis of MHE is thought to be similar to that of overt HE and ammonia 
plays a key role.12-14 Ammonia induced alterations in cerebral blood flow and glucose 
metabolism have shown that there is a significant decrease of glucose utilization of 
various cortical regions that correlate with the patients cognitive functions.14 Various 
treatment modalities have been tried to treat this condition e.g., dietary protein 
manipulation, 15 branched-chain amino acids, 16 L–ornithine L aspartate,17 and lactulose.4, 
18, 19 Most of these therapies were aimed to reduce ammonia levels.
Non absorbable disaccharides:
         Lactulose is the most common agent used in the treatment of MHE. Treatment with 
lactulose is of benefit in majority of patients with MHE.4, 18,19 Watanabe et al showed that 
MHE disappeared in 50% of pts treated with lactulose for 8 weeks but persisted in 85% of 
untreated pts.19 We found marked improvement in psychometric tests with lactulose 
administration for 3 months; MHE disappeared in 8/10 patients on lactulose but persisted 
in all 8 untreated patients.18 Lactulose lowers ammonia levels by alteration in gut flora 
resulting in decreased production and absorption of ammonia. 
           Dhiman and co-workers for the first time investigated the effect of treatment related 
improvement in cognitive functions on health related quality-of-life (HRQOL).4 We 
measured psychometric performance by number and figure connection tests A 
and B, picture completion and block design tests, and HRQOL by Sickness Impact Profile 
(SIP) in 90 cirrhotic patients at inclusion into the study and 3 months thereafter. 
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         Sixty-one (67.7%) patients had MHE. They were randomly assigned in a 1:1 ratio to 
receive treatment (lactulose) for 3 months (n=31) or no treatment (n=30) in a non-blinded 
design. Mean number of abnormal NP tests decreased significantly in patients in treated 
group compared with patients in untreated group (MANOVA for time and treatment, P 
=.001). Intention to treat analysis showed that improvement following lactulose therapy 
was significant. While 20 out of 31 (64.5%) patients in treated group improved, 2 of 30 
(6.7%) patients did so in untreated group (Fisher’s exact test; P < .0001). Mean total SIP 
score improved among patients in the treated group compared with patients in untreated 
group (MANOVA for time and treatment, P=.002). Improvement in HRQOL was related to 
the improvement in psychometry. Thus treatment with lactulose improves both cognitive 
functions and HRQOL in cirrhotic patients with MHE. 
 
32
32
32
 Table 6: Treatment with lactulose
Author
(year)
MHE (N) Duration of treatment Result
Wantabe et al
(1997)
36
Lactulose 22
Placebo 14
8 weeks Lactulose better than placebo
Dhimen et al
(2000)
26
Lactulose 14
Placebo 12
3 months Lactulose better than placebo
Zeng  et al
(2003)
60 8-24 weeks Lactulose better than placebo
Prasad et al
(2007)
61
Lactulose 31
Placebo 30
3 months Lactulose improves cognitive 
and SIP score
 Prebiotics and Synbiotics
       Treatment with synbiotics (probiotics and fermentable fiber) has been suggested but 
not assessed in controlled studies in the treatment of MHE. Liu et al 3 reported an 
alternative and novel approach of modulating the gut micro ecology and acidifying the gut 
lumen for therapeutic benefit in cirrhotic patients with MHE by treatment with synbiotics. 
The investigators of this study have attempted to confirm the usefulness of synbiotics in 
the treatment of MHE. They screened 97 consecutive cirrhotic patients without overt 
hepatic encephalopathy (HE) for MHE using the number connection test (NCT) and 
measurement of BAEP. 
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         MHE, defined by abnormality of at least one test modality, was seen in 58 (60%) 
patients. Fifty-five of them MHE were randomized to receive a synbiotic preparation i.e., a 
probiotic plus fermentable fiber
(n=20), fermentable fiber (n=20), or placebo (n=15) for 30 days. Probiotic compound 
consisted of 4 freeze-dried, non-urease-producing bacteria, namely Pediacoccus 
pentoseceus, Leuconostoc mesenteroides, Lactobacillus paracasei subspecies paracasei 
19 and Lactobacillus plantarum 2592, each at dose of 1010 colony forming units per 
sachet. 
        Fermentable fiber consisted of beta glucan, 2.5 g; insulin 2.5 g, pectin 2.5 g, and 
resistant starch, 2.5 g. Placebo consisted of wheat based nonfermentable fiber. Patients 
were evaluated with NCT and BAEP, serum ammonia and endotoxin levels, and stool 
quantitative bacteriological analysis at study entry, after 1-month of treatment and again 
after 14 days. Cirrhotic patients with MHE had substantial derangements in the gut micro 
ecology, with significant fecal overgrowth of potentially pathogenic Escherichia coli and 
Staphylococcal species.
       Synbiotic treatment significantly increased the fecal content of non-urease-producing 
Lactobacillus species at the expense of these other bacterial species. The effect persisted 
at reassessment 14 days after cessation of supplementation. Such modulation of gut flora 
was associated with a significant reduction in blood ammonia levels and reversal of MHE 
in 50% of patients. Synbiotic treatment was also associated with a significant reduction in 
endotoxemia. 
e
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        The Child-Turcotte-Pugh functional class improved in nearly half of patients. Similar 
benefit was observed with fermentable fiber alone in a substantial proportion of patients. It 
may be concluded that the treatment with synbiotic or fermentable fiber is an alternative to 
lactulose for management of MHE in patients with cirrhosis. Shall we routinely screen 
cirrhotic patients for the presence and treatment of MHE 59 Recently published literature 
favors it.
              S. K. Sarin et al20 (2007) studied156 cirrhotic patients (age 41 ± 12.5 yr) without 
overt encephalopathy  were evaluated by psychometric (number connection tests A, B or 
figure connection tests A, B), P300 auditory event related potential (ERP) and CFF. MHE 
was diagnosed by abnormal psychometric and/or P300 auditory event related potential.
           Prevalence of MHE was 53% with 27 (43%) in Child’s A, 33 (59%) in Child’s B and 
23 (62%) in Child’s C cirrhosis (p = NS). Of 83 patients, 72 (87%) had abnormal 
psychometry, 64 (77%) had abnormal P300 auditory event related potential (ERP) 
(380.6 ± 28.8 ms) and in 66 (80%) CFF was below 39 Hz. 60 (83%) patients with 
abnormal psychometry and 51 (80%) with abnormal P300 auditory event related potential 
had CFF below 39 Hz. CFF sensitivity (96%), specificity (77%) and positive predictive 
value (68%), negative predictive value (98%) and diagnosis accuracy was 83.3% when 
compared to patients  with both abnormal psychometry and P300 Event Related 
Potentials Critical flicker frequency is a simple, reliable and accurate test without any age 
or literacy dependence for the diagnosis of MHE. 
             Schomerus et al21 (2008) conducted the neuropsychological function testing in 
292 liver cirrhosis patients without overt hepatic encephalopathy and then assessed them 
in regard to fitness to drive. He developed an easily conducted 
computer-aided quantitative neuropsychological function test system for use in routine 
medical practice. The system was used prepare basic values according to age in 542 
healthy subjects and the results were compared with 292 liver cirrhosis patients.
          The software is composed of eight tests: Number Connection Test -A, Number 
Connection Test -B, Figure Design Test, Digit Symbol Test, Block Design Test and the 
Reaction Time-A, Reaction Time-B and Reaction Time-C.
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          The results showed that 60% of the patients were unfit to drive a motor vehicle. The 
results also showed that 25%of the patients were capable of limited driving only. The 
investigators also found significantly more persons unfit to drive in an alcoholic liver 
cirrhosis group than in a non-alcoholic liver cirrhosis group.      
            K. Dhiman et al22 (2004) screened 97 consecutive cirrhotic patients without overt 
hepatic encephalopathy (HE) for MHE using the 
- number connection test (NCT) and 
- measurement of brainstem auditory evoked potentials (BAEP). 
     The cause of cirrhosis was hepatitis virus B or C in 
75 (77%) patients, alcohol in 19 (20%) and other in 3 (3%). Patients with alcoholic 
hepatitis were carefully excluded. 
      He concluded that Combination of at least 
- 2 psychometric 
(trail making tests, block design or digit symbol test) and 
- 1 neurophysiological test 
(P300 BAEP or electroencephalography with mean dominant frequency) 
seems to be optimal in detecting MHE in cirrhosis patients. M.F. El-Shater et al23 
(2007) studied 43 well-compensated cirrhotic patients without signs of encephalopathy 
were studied by neuropsychological cognitive test battery, P300 ERP latency, EEG, 
conventional MRI brain. The patients were followed-up for 2 yrs. to monitor subsequent 
episodes of overt encephalopathy. Child-Pugh classification was done throughout the 
study to assess severity of liver cirrhosis. Forty-six healthy subjects, age, sex and 
education matched, served as a control group.
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         Minimal HE was diagnosed in 21(48.8%) out of 43 cirrhotic patients. Inverted sleep 
rhythm was reported in 85.7%, of cirrhotic with MHE. Delayed P3ERP latency was seen in 
38.1% of cirrhotic patients with MHE, while Number Connection Test (NCT-A & B) times 
were prolonged in 71.4% of the patients. EEG abnormality was detected in 47.6 %, while 
MRI signs were reported in 80.9% of cirrhotic with MHE. Out of 43 patients, 18(41.8%) 
developed overt encephalopathy, 66.7% of the patients with MHE progressed to overt 
encephalopathy within a mean duration of 9 months, while only 13. 6% of the non-MHE 
patients did so. Of the patients who developed overt encephalopathy, 83.3% had 
abnormal EEG, 77. 8 % had abnormal NCT, while 59. 3% had P3ERP latency 
prolongations.
 
        D. Antonicelli et al24 (2007) studied 182 consecutive pts, without overt 
encephalopathy. (142 pts, 97 men and 45 women; age 20-70; 94 Child A, 44 Child B and 
4 Child C) only psychometric tests were performed in order to study the prevalence of 
MHE. The remaining 40 pts (29 men, 11 women; age 20-70; 27 Child A, 12 Child B, 1 
Child C), underwent both psychometric and neurophysiological tests (only in ten pts, they 
performed CFFF). In addition, this group of 40 pts was clinically 
evaluated by neurologists and oculists, in order to exclude neurological or ocular disease 
that could have affected neurophysiological tests. 
         All tests were validated in normal subjects who served as control group. Eighty pts 
out of 142 (57%) resulted affected by MHE using psychometric tests. By intention to treat 
analysis, in the remaining 40 pts they obtained the following results: abnormal 
psychometrics in 21 patients (52.5%), abnormal BAEP in 19 patients (47.5%), abnormal 
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CFFF in 7 out of 10 patients (70%)  Neurophysiological tests, in particular CFFF, 
ameliorate
the diagnostic sensitivity for MHE.
 
         M L Zeneroli et al 25 (1984) , studied visual evoked potential recordings  in 45 liver cirrhosis 
patients with (n = 29) and without (n = 16) encephalopathy, in 15 normal volunteers, and in one 
patient with an opioid induced stupor state. Visual evoked potential parameters were classified on 
the basis of EEG recordings. Plasma concentrations of amino acids, octopamine, and ammonia were 
assayed in order to document the metabolic change of hepatic encephalopathy. Latencies and wave 
patterns recorded after flash stimulation differentiated the four degrees of the coma one from 
another according to EEG classification in the 29 patients with encephalopathy. 
          In the group of 16 patients without clinical and EEG evidence of encephalopathy the visual 
potential recordings discriminated a group of patients (n = 10) in a preclinical stage of 
encephalopathy. Biochemical parameters and subsequent clinical observation of patients confirmed 
our judgment of a preclinical stage of encephalopathy. These results suggest that visual evoked 
potentials are a 
simple, suitable and objective method for differentiating the degrees of encephalopathy and for 
identifying the preclinical stage of encephalopathy.
            M. G. Davies et al 26 (1990), studied the value of the flash visual evoked response 
(VER) in patients with MHE. Twenty-six controls and 21 non-encephalopathy and 12 
encephalopathy (grade 1/ 2), biopsy-proven, cirrhotic patients were assessed clinically, 
psychometrically, and electro physiologically. Flash VER from three different leads were 
obtained from each patient. Data from the fronto-occipital leads gave the best 
differentiation between the subjects. 
          The P2 and N3 peak latencies were significantly increased in the two liver groups 
and correlated with the mental state and psychometric results. The N3 latency had a 92% 
specificity and a 50% sensitivity in the detection of grade 1/2 HE. This study suggests that 
the N3 latency changes may be a good marker of early clinical HE and useful in the 
longitudinal assessment of individual patients. 
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        Neville L. Sandford et al27 (2005), studied Thirty-six patients with advanced chronic liver 
disease of predominantly alcoholic etiology and with a documented history or current physical 
evidence of hepatic encephalopathy were studied and compared to 30 healthy controls. Assessment 
was made of their mental state, number connection test, venous blood ammonia, 
electroencephalography and visual evoked potentials with both pattern reversal and flash stimuli. 
        Because of considerable inter- and intraindividual variation in waveform, visual evoked 
potentials from flash stimuli were considered unreliable. In pattern reversal visual evoked 
potentials, the latency of the N1 and P1 waves was significantly longer 
(p < 0.05) in patients than in controls; however, the wave latencies did not correlate with the mental 
state score. The mental state score correlated with the number connection test (r = 0.69, p < 0.001), 
asterixis (r = 0.36, p < 0.05), electroencephalography mean dominant frequency (r = 0.44, p < 0.01) 
and blood ammonia (r = 0.60, p < 0.01). 
        In 14 patients studied sequentially, change in the mental state score correlated with change in 
the number connection test (r = 0.80, p < 0.01) and asterixis (r = 0.75, p < 0.01) but not with change 
in the electroencephalography, blood ammonia or visual evoked potential wave latencies. Although 
visual evoked potentials are abnormal in patients with alcoholic cirrhosis and encephalopathy, they 
are less accurate in assessing the level of consciousness than simple bedside evaluation with a 
number connection test.
          Parampreet S Kharbanda et al28 (2003) studied cognitive deficits found on 
neuropsychological and/or neurophysiologic methods in patients with liver disease, present most 
commonly in cirrhosis. Patients suffering from MHE may have psychomotor slowing and cognitive 
deficits affecting their ability to perform many activities of daily life, especially driving and other 
activities requiring subtle cognitive abilities. It has been now been shown that patients with MHE 
improve after treatment with agents like lactulose and other therapeutic interventions. 
         Neuropsychological and neurophysiologic tests have been widely used and have shown the 
greatest promise for the detection of MHE. Commonly used psychometric tests include trail making 
tests (number and figure connection tests) and Wechsler Adult Intelligence Scale (WAIS) for 
verbal and performance skills. Among the various neuropsychological or psychometric tests, trail 
making tests and 
block design and digit symbol tests from WAIS-performance battery appear to be adequate for 
diagnosis of MHE.
        Standardized tests including NCT A and B, line tracing, serial dotting test and digits-symbol 
test (PSE syndrome test) validated in German patients need validation in other populations. Both 
exogenous evoked potentials and endogenous event-related potentials have been used extensively 
in diagnosing MHE. However, the event-related P300 wave is the most consistent wave and can be 
considered the electrophysiological counterpart of the psychometric tests as both involve active use 
of the cognitive faculties. Other new tests like the critical flicker frequency have shown some 
promise but further studies are required to substantiate initial results. 
          In conclusion, a combination of at least two psychometric (trail making tests [NCT or FCT], 
block design and digit symbol test) and neurophysiological tests (P300 auditory evoked potential or 
electroencephalography with mean dominant frequency) appears to be optimal in detecting MHE.
          M. Senzolo et al29 (2004) studied 114 patients, (aged 58,2±8,5 years) with liver 
cirrhosis they underwent PSE (digit symbol test, trail making A and B, serial dotting and 
line tracing test, single test score +1,-3) to classify patients with MHE (total score<-4). 
Neurophysiological evaluation was performed with spectral quantitative EEG (sEEG) with 
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relative band power calculation. and analysis of interpeak latency of evoked potential 
wave P300. pNH3 (x10–5mmHg), venous and arterial levels of ammonia were also 
assessed. 
         PSE score revealed MHE in 3/14 patients and sEEG alteration seen in 6/14 patients 
(2/6 with also pathological PSE score). Length of interpeak latency P300 
was pathological in 1/14 patients. No correlations between P300, sEEG and PSE were 
seen. pNH3 levels were significantly higher in patients with sEEG alteration (p<0,01). 
pNH3 and arterial ammonia correlated with theta band increase in sEEG. pNH3 did not 
correlate with pathological PSE score or P300 wave abnormalities. 
        sEEG, that correlates with pNH3 levels, but not with arterial or venous ammonia 
concentrations, seems to be a useful tool to diagnose cerebral function alterations in 
cirrhotic patients without overt EPS. PSE Syndrome Test and P300 seem to be less useful 
compared to sEEG in diagnosing MHE.
        Jasmohan S. Bajaj et al30 (2008) studied the reliability and validity of Inhibitory 
Control Test (ICT) for MHE diagnosis. ICT was compared with a psychometric battery 
(standard psychometric tests [SPT]) for MHE diagnosis and overt hepatic encephalopathy 
(OHE) prediction. ICT was administered twice for test-retest reliability, before/after 
transvenous intrahepatic portosystemic shunting (TIPS), and before/after yogurt 
treatment. The time taken by 2 medical assistants (MA) to administer ICT was recorded 
and compared with that of a psychologist for cost analysis.
        136 cirrhotic patients and 116 age/education-matched controls were studied. ICT (>5 
lures) had 88% sensitivity for MHE diagnosis with 0.902 area under the curve for receiver 
operating characteristic. MHE-positive patients had significantly higher ICT lures (11 vs 4, 
respectively, P = .0001) and lower targets (92% vs 97%, respectively, P = .0001) 
compared with MHE-negative patients. The test/retest reliability for ICT lures (n = 50, r = 
0.90, P = .0001) was high. ICT and SPT were equivalent in predicting OHE (21%). ICT 
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lures significantly worsened after TIPS (n = 10; 5 vs 9, respectively; P = .02) and improved 
after yogurt supplementation (n = 18, 
10 vs 5, respectively; P = .002). The MAs were successfully trained to administer ICT; the 
time required for test administration and the associated costs were smaller for ICT than for 
SPT. Concluded that ICT is a sensitive, reliable and valid test for MHE diagnosis that can 
be administered inexpensively by MAS.
          Piero Amodio et al31(2008) studied patients by using Psychometric Hepatic 
Encephalopathy Score (PHES) and EEG to detect minimal hepatic encephalopathy 
(MHE). They aimed at standardizing PHES in Italy and comparing Italian, German and 
Spanish norms in EEG characterized cirrhotic patients.
          PHES was standardized on 228 normal individuals. Repeatability was studied in 
128 individuals. One hundred patients with liver cirrhosis underwent EEG and PHES 
which was computed on the Spanish, German and the Italian norms.
         Age and education levels were predictors of psychometric tests; therefore, adjusted 
Z scores were calculated. Practice effect (p < 0.01) was detected. In the patients, the 
Italian norms were closer to the Spanish norms (difference _0.14 ± 1.32, p = 0.29) than to 
the Germans ones (difference 1.97 ± 2.07, p < 0.001). The PHES calculated on the Italian 
norms was correlated with the EEG mean dominant frequency more closely than the ones 
calculated on the German and Spanish norms (r = 0.38, r = 0.31, r = 0.33, respectively – p 
< 0.01). The detection of MHE on the basis of PHES and EEG showed limited agreement 
(73%, Cohen’s K = 0.32).Different findings between PHES and EEG possibly reflect 
various features of MHE.
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         Andrzej Habior et al32 (2009) In patients with liver cirrhosis, minimal hepatic 
encephalopathy (MHE) is associated with a poor quality of life and difficulty in driving. It 
has also been suggested that MHE can precede the development of overt hepatic 
encephalopathy (OHE). No gold standard exists to detect MHE. Therefore the prevalence 
of this entity varies depending on the diagnostic methods used. 
         51 patients with liver cirrhosis and portal hypertension (29 with primary biliary 
cirrhosis, 22 with HCV infection) were studied. In all patients they performed seven 
diagnostic tests: four psychometric tests (NCT-A, NCT-B, DST, BDT), EEG, spectral EEG, 
P300 auditory event related potential, critical flicker frequency (CFF), proton magnetic 
resonance spectroscopy of the brain (1HMRS) and serum concentration of astroglial 
protein S100 .Patients were followed up for a period of 4 years.
        Based on the psychometric tests, 9 out of 51 patients (17.6%, 95% CI 7-28) were 
diagnosed to have MHE. If the results of EEG, P300 and spectral EEG were added, the 
prevalence of MHE raised to 16 of 51 patients (31.3%, 95% CI 18-44). Addition one 
nonstandard test (CFF, 1HMRS or S100) raised the percentage of patients suspected of 
MHE to above 40%. 
        During follow up OHE developed in 14 patients but MHE in this group was earlier 
diagnosed using psychometric tests in only 10 patients. Twelve of 14 patients with OHE 
had at least one abnormal result out of the seven tests. Multiple proportional hazard 
regression model showed a higher risk of OHE in patients with abnormal EEG (HR - 8.4, 
95% CI 2.6 -27.3, p < 0.001). Other factors, including psychometric and standard and 
nonstandard tests, did not predict the OHE. Diagnosis of minimal hepatic encephalopathy 
needs further standardization. Among 
the seven different diagnostic methods, only EEG has a predicting value for minimal 
hepatic encephalopathy in cirrhotic patients.
42
42
42
              
MATERIALS AND METHODS
       The centre of study was Department of Medical Gastroenterology,  Madras Medical 
College and Government General Hospital, Chennai.
Study Design :     Prospective study
Venue                                 :    Government General Hospital,   Chennai
Duration  :      From January 2008 to December 2008 (12  months)
Collaborating Department :     Department of Neurology, 
                                       Government General Hospital, Chennai.
       Fifty patients who attended Medical Gastroenterology outpatient department with a 
clinical  diagnosis of cirrhosis of liver by clinical,  radiological and laboratory parameters 
included in the study. 
Patient selection
Inclusive criteria
1. Patients with a clinical diagnosis of cirrhosis of liver of any etiology.
2. Patients with Child class A.
3. Patients with no clinical evidence of encephalopathy.
P
Exclusion criteria
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1. Patients with Child class B and C
2. Uneducated patients who are unable to perform NCT
3. Patients with overt encephalopathy 
4. Severe hypertension
5. Heart disease
6. Diabetes
7. Cerebrovascular and other brain diseases
8. Respiratory failure
9. Renal failure
10. Psychiatric diseases
Protocol
1. All patients who met the above criteria were included in the study and got admitted 
in our department.
2. The following were noted in each patient
(i) Age
(ii) Sex
(iii) Educational status
(iv) Duration of abdominal distension
(v) H/o Swelling of legs + / -
(vi) H/o Jaundice
(vii) H/o of G. I. Bleed
(viii)
(
(ix) H/o altered sleep rhythm
(x) H/o Bleeding tendencies (epistaxis, gum bleeding, hematuria etc)
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(xi) H/o Abdominal pain
(xii) H/o Breathlessness on exertion
(xiii) Past H/o jaundice
(xiv) Past H/o blood transfusions 
(xv) Past H/o tattooing
3. A thorough physical examination was done in all the fifty patients.  Signs of chronic 
liver  disease  with  portal  hypertension  like  palmar  erythema,  spider  nevi, 
gynaecomastia, large abdominal wall  collaterals (caput medusa),  fetor hepaticus 
and asterixis were noted.
Examination of central nervous system was done in detail.
      Investigations
The following investigations were done in all fifty patients.
1. Liver function tests including Prothrombin time / INR
2. Ultra sonogram of the abdomen
3. Diagnostic upper G. I. Endoscopy
4. NCT done at the bedside
5. Electroencephalogram
6. Brainstem auditory evoked potential
B
Number Connection Test:
                After admission in the ward patients were given the Reitan’s trail marking 
chart 80 and asked to connect the numbers in an orderly manner and the time taken to 
complete the test was recorded. Patients with normal mental function will complete the 
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test within 90 seconds, hence the test is considered abnormal if the patient is not able 
to complete the test within 90 seconds. 
                  Reitan’s trail making chart
 
          Electroencephalogram (EEG) and Brainstem auditory evoked potentials (BAEP) 
were done for all patients in the department of Neurology, Government general hospital, 
Chennai itself  and findings were collected and recorded.
                            Fig 2: Nicolet Bravo EEG 
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                                            Results 
          Thirty four male (68%), 16 (32%) female patients, mean age was 45.6 years. All of 
them are Child A class functional status patients. Ethanol related cirrhosis in 29 patients 
(58%), Post necrotic ( HBV related) cirrhosis in 7 patients (14%), Cryptogenic cirrhosis in 
14 patients (28%), Number connection test (NCT) was abnormal in 24 patients (48%), 15 
patients had abnormal Electroencephalogram (EEG) suggestive of diffuse bilateral 
cerebral dysfunction (30%),  12 patients had abnormal brainstem auditory evoked 
potentials (BAEP) in the form of abnormal prolongation of latency and asymmetry (24%), 7 
Patients had both abnormal NCT and EEG (14%), 7 Patients had both abnormal NCT and 
BAEP (14%), 6 Patients had both abnormal EEG and BAEP (12%), Only 3 patients had 
abnormal NCT, EEG and BAEP (6%), About 2/3rd of the patients were males (68%). 
Abnormal tests found in 42% of patients in the age group  40- 50years, 28% of patients in 
the 30-40 years age group, 20 % of patients in 50-60 years age group, only 8% in 60- 
70years age group and only one patient (2%) in 70-80 years age group.
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                                                           DISCUSSION
                About one hundred (100) articles have been published in various national and 
international journals about the importance of Number connection test (NCT), 
Electroencephalogram (EEG) and Brainstem auditory evoked potentials (BAEP) to find out 
the prevalence of minimal hepatic encephalopathy.
               In this study 64% of patients had minimal hepatic encephalopathy detected by 
either abnormality in single test alone [abnormal NCT alone (48%)  or EEG alone (30%) or 
BAEP alone (24%)] or combination of 2 abnormal tests (20 patients (40%) had 
abnormality in two tests) or  three abnormal tests (3 patients (6%) had abnormality in all 
the three tests), NCT alone is abnormal in 48% of patients, EEG was abnormal in 30% of 
patients and BAEP was abnormal in 24% of patients, this prevalence is more than that 
observed in S.K. Sarin study (2007),wherein the prevalence was only 73% and abnormal 
psychometric test was seen in 87% of patients, abnormal event related potential in 77% of 
patients when comparing this study it is almost two to three fold increased incidence this 
may be due to inclusion of Child B and C patients in their study. 
               Prevalence of MHE using EEG in this study is 30%, it is similar to the study by 
Groenweg (2000) - 27%. Prevalence of MHE  in this study using BAEP is only 24%, it is 
much lower when comparing other studies, Yen et al (1990) – 60%, Lin et al (2004) – 60% 
this difference is probably due to inclusion of patients with Child B and C in their studies.
                Another study by Schomerus (2008) showed 60% of patients had minimal 
hepatic encephalopathy in the form of poor driving skills most of them had ethanol related 
cirrhosis, similarly in this study also 58% of patients had ethanol related cirrhosis, 28% 
had cryptogenic and 14% had HBV related cirrhosis.
                 When comparing available studies  with this study in relation to etiology of 
cirrhosis most common etiology in other studies is virus related either HBV or HCV in 77% 
of patients in Dhiman et al (2004) but in this study ethanol is being the most common 
etiology with the peak incidence of age distribution is between 40 – 50 years age group, 
this is because cirrhotics with viral etiology coming for treatment late with severe disease 
unlike ethanol related cirrhotics. In  Akinobu Kato et al (2008) series etiology of cirrhosis 
viruses both HBV and HCV in 81%, Ethanol in 13% and other causes in 6% of patients 
                   In this study age group between 40-50 years  has the highest prevalence of 
MHE it is 42%, followed by 28% in the 30 -40 years group, and then 20% in the 50 
-60years group. But in the study by Akinobu et al (2008) highest prevalence of MHE in the 
age group between 60-64 years (28%), in the 65-69 years age group prevalence is 28%, 
lowest prevalence of 5% in 40-44 years group, probably this may need more sample size 
to analyze that age group difference.
                  In this study sex distribution is males 34 (68%) and female 16 (32%), sex 
distribution is similar to  Akinobu Kato study (2008) wherein male 66% and female 34%. 
Prevalence of MHE using NCT in this study is 48%, is similar to other available studies 
Yen et al (1990) - 60%, Lin et al (2004) - 60%, Sharma et al (2007) – 53%, Groenweg et al 
(2000) – 27%, Das et al (2001) – 63%, Prasad et al (2007) – 68%.
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CONCLUSION
              Minimal Hepatic Encephalopathy is proved undoubtedly impairs quality of life 
observed in patients with cirrhosis who have no overt encephalopathy, medical 
intervention can improve both cognitive function and health related quality of life.
                   Hence screening for Minimal Hepatic Encephalopathy is important in cirrhotics 
to provide them a good quality of life, driving skills which is impaired in Minimal Hepatic 
Encephalopathy by interfering at the early stage of the disease to prevent progression to 
overt encephalopathy which has got a high mortality.
            Diagnosis of MHE requires high index of suspicion, useful three diagnostic tools 
are NCT, EEG and BAEP. This study showed 48% had abnormal NCT, 30% had 
abnormal EEG, 24% had abnormal BAEP with combined prevalence of MHE 64%.
 
            This study suggested that Number connection test (NCT), Electroencephalogram 
(EEG) and Brainstem auditory evoked potentials (BAEP) are valid tools for the screening 
of minimal hepatic encephalopathy in cirrhotic patients of various etiology as there is a 
greater likelihood of overt encephalopathy development in the immediate follow up period 
in patients with an abnormality detected by these tests than in patients with no such 
abnormality. 
              Seven patients developed overt encephalopathy within a period of 2months in the 
one year follow up period. Large scale study may be needed to enlighten these aspects. 
These tools can be used for screening for MHE in patients with cirrhosis. 
T
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A Study On Minimal Hepatic Encephalopathy
PROFORMA
S. No.
Name : Age: Sex:
Educational status:
Occupation:
Address:
Contact No.:
Hospital No.:
Symptoms:
i) Abdominal distension
ii) Swelling of legs
iii) Jaundice
iv) Blood vomiting
v) Abdominal pain
vi) Altered sleep rhythm / altered sensorium
vii) Bleeding tendencies
60
60
60
6
61
61
61
PAST HISTORY
i) Jaundice
ii) Abdominal surgeries
iii) Blood transfusion
iv) Tattooing
PERSONAL HISTORY
i) Alcohol
ii) Smoking
iii) Drug abuse
iv) Marital Status
v) Promiscuity
EXAMINATION
Consciousness : Orientation :
Pallor : Y/ N Jaundice : Y / N          Pedal edema  
:
Lymphadenopathy : JVP :
Signs of CLD :
Cutaneous bleed  :
Ascites :
Hepatosplenomegaly :
Abdominal wall collaterals :
Asterixis             :
62
62
62
INVESTIGATIONS
1. Liver function tests
T. Bilirubin :
D. Bilirubin : T. Protein :
                      Albumin :
AST : Globulin :
ALT :
2. Prothrombin Time / INR
3. Ultrasonography of the abdomen 
4. Diagnostic Upper GI Endoscopy
5. Number Connection Test (NCT)
6. Electroencephalogram (EEG)
7. Brainstem auditory evoked potential (BAEP)
63
63
63
            Master chart
Sl No
Name
Age.
Sex
Etiology of cirrhosis
NCT
EEG
BAEP
1
Mahendran
42
M
Alcohol
Abnormal
Normal
Abnormal prolongation of latency and asymmetry
2
Arunachalam
44
M
Alcohol
Normal
Abnormal suggestive of B/L cerebral dysfunction
Normal
3
Lalitha
38
F
Cryptogenic
Normal
Normal
Normal
4
Krishnan
44
M
Alcohol
Normal
Abnormal suggestive of B/L cerebral dysfunction
Abnormal prolongation of latency and asymmetry
5
Anandhi
37
F
64
64
64
Cryptogenic
Abnormal
Normal
Normal
6
Mahendri
45
F
HBV
Normal
Abnormal suggestive of B/L cerebral dysfunction
Normal
7
Saravanakumar
34
M
Cryptogenic
Abnormal
Normal
N
8
Venkateshwar
41
M
Alcohol
Normal
Normal
Abnormal prolongation of latency and asymmetry
9
Ponnamma
45
F
HBV
Normal
Normal
Normal
10
Kameshwari
52
F
Cryptogenic
Abnormal
Abnormal suggestive of B/L cerebral dysfunction
Normal
11
Sakuntala
52
F
HBV
65
65
65
Normal
Normal
Normal
12
Rajadurai
45
M
Alcohol
Abnormal
Normal
Abnormal prolongation of latency and asymmetry
13
Rajalakshmi
76
F
Cryptogenic
Normal
Abnormal suggestive of B/L cerebral dysfunction
Normal
14
Ramesh
36
M
Alcohol
Abnormal
Normal
Normal
15
Indrani
47
F
Cryptogenic
abnormal
Normal
Normal
16
Lakshmanan
58
M
Alcohol
Normal
Normal
Normal
17
Venkateshwari
39
F
Alcohol
Normal
66
66
66
Abnormal suggestive of B/L cerebral dysfunction
Abnormal prolongation of latency and asymmetry
18
Anbalagan
41
M
Cryptogenic
Normal
Normal
Normal
19
Lakshmanan
43
M
Cryptogenic
Abnormal
Normal
Normal
20
Dhanalakshmi
43
F
Alcohol
Abnormal
Normal
Normal
21
Malliga
35
F
Cryptogenic
Normal
Abnormal suggestive of B/L cerebral dysfunction
Normal
22
Mani
48
M
Alcohol
Abnormal
Normal
Abnormal prolongation of latency and asymmetry
23
Rajeshwari
38
F
Alcohol
Abnormal
67
67
67
Normal
Normal
24
Murugan
47
M
Cryptogenic
Abnormal
Abnormal suggestive of B/L cerebral dysfunction
Normal
25
Thiagarajan
38
M
Alcohol
Abnormal
Normal
Normal
26
Murugesan
54
M
HBV
Abnormal
Abnormal suggestive of B/L cerebral dysfunction
Abnormal prolongation of latency and asymmetry
27
Rajendran
45
M
Cryptogenic
Abnormal
Normal
Normal
28
Savithri
69
F
Cryptogenic
Normal
Normal
Normal
29
Kamaladevi
36
F
HBV
Abnormal
Abnormal suggestive of B/L cerebral dysfunction
68
68
68
Normal
30
Thangavel
60
M
Alcohol
Abnormal
Normal
Normal
31
Hari
50
M
Alcohol
Normal
Normal
Normal
32
Viswanathan
40
M
Alcohol
Abnormal
Normal
Abnormal prolongation of latency and asymmetry
33
Dhanapal
39
M
Alcohol
Normal
Normal
Normal
34
Ramasamy
47
M
HBV
Normal
Abnormal suggestive of B/L cerebral dysfunction
Normal
35
Madhu
43
M
Alcohol
Abnormal
Normal
Normal
69
69
69
36
Ramachandran
39
M
Cryptogenic
Normal
Normal
Normal
37
Adiappan
37
M
Alcohol
Normal
Normal
Abnormal prolongation of latency and asymmetry
38
Kanniappan
60
M
Alcohol
Abnormal
Normal
Normal
39
Balaraman
45
M
Alcohol
Abnormal
Abnormal suggestive of B/L cerebral dysfunction
Normal
40
Balan
42
M
Cryptogenic
Normal
Normal
Normal
41
Ramayee
61
F
Alcohol
Abnormal
Abnormal suggestive of B/L cerebral dysfunction
Abnormal prolongation of latency and asymmetry
70
70
70
42
Chinnathambi
54
M
Alcohol
Abnormal
Normal
Normal
43
Simon
43
M
HBV
Normal
Normal
Normal
44
Suseela
39
F
Alcohol
Normal
Normal
Normal
45
Nainan
56
M
Alcohol
Abnormal
Abnormal suggestive of B/L cerebral dysfunction
Abnormal prolongation of latency and asymmetry
46
Gopal
37
M
Alcohol
Normal
Normal
Normal
47
Palani
45
M
Alcohol
Normal
Normal
Normal
48
71
71
71
Venkatesan
41
M
Alcohol
Normal
Normal
Normal
49
Mahalingam
38
M
Alcohol
Normal
Normal
Normal
50
venugopal
52
M
Alcohol
Normal
Abnormal suggestive of B/L cerebral dysfunction
Abnormal prolongation of latency and asymmetry
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PATIENT CONSENT FORM
STUDY TITLE : A Study On Minimal Hepatic Encephalopathy 
Study Centre : Department of  Medical Gastroenterology, MMC, GGH, Chennai – 
600003.
Patient’s Name :
Patient’s Age :
Identification Number :
Patients may check () these Boxes
I  confirm that I  have understood the purpose of procedure for the above 
study.  I have the opportunity to ask the questions and all my questions and 
doubts have been answered to my complete satisfaction. [     ]
I understand that my participation in the study is voluntary and that I am free 
to withdraw at any time without giving any reason, without my legal right 
being affected [     ]
I  understand  that  sponsor  of  the  clinical  study,  others  working  on  the 
sponsor’s   behalf, the ethics committee and the regulatory authorities will 
not need my permission to look at my health records both in respect of the 
current study and any further research that may be conducted in relation to 
it,  even  if  I  withdraw  from  study.   I  agree  to  this  access,  however,  I 
understand that  my identity would  not  be  revealed.   In  any  information 
released to third parties or published, unless as required under the law.  I 
agree not to restrict the use of any data or results that arise from this study.
[     ]
I agree to take part in the above study and to comply with the instructions 
given during the study and to faithfully to cooperate  with the study team, 
and to immediately inform the study staff if I suffer from any deterioration in 
my health or my well being or any unexpected or unusual symptoms.
[     ]
I hereby give consent to participate in this study . [     ]
Signature/  Thumb  Impression  of  the 
patient:
....................................................................
...........
Place : ..................................................
Patient’s name and address: ....................................................................
...........
Signature of the Investigator ...................................Place ............. 
Date ...............
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Name of the Investigator ..................................................
